PIRAMAL PHARMA LIMITED
₹239.05+₹8.45 (+3.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹22,363 Cr
- P/E
- 31.7x
- EV / EBITDA
- 27.6x
- Revenue
- ₹5,286 Cr
- Net margin
- 8.9%
- ROCE
- 7.8%
Price chart
Technical chartScreen technicals →+18.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +15.9%
- 3M
- +21.4%
- 6M
- +47.7%
- 1Y
- +18.4%
- 5Y
- +38.1%
52-week range
Day change +₹8.45 (+3.7%) from ₹231 to ₹239 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in PPLPHARMA, bought on each weekday since 2022.
AI Summary
Indian StockStrengths1
- Revenue grew 20.4% YoY
Concerns1
- Low return on equity of 5.8%
Rule-based from financial data. Not advice.
About the company
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network.
Read moreShow less
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 133 Cr shares
- ISIN
- INE0DK501011
- BSE code
- 543635
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹22,363 Cr
- P/E
- 31.7x
- P/B
- 2.9x
- EV / EBITDA
- 27.6x
- EV / Sales
- 5.1x
- P/S
- 5.1x
- Earnings yield
- 3.2%
- 52-week high
- ₹239.05
- 52-week low
- ₹133.05
Profitability
- Operating margin
- 14.1%
- Net margin
- 8.9%
- EBITDA margin
- 18.7%
- ROE
- 5.8%
- ROCE
- 7.8%
- ROA
- 4.1%
- Dividend payout
- 4.0%
- Tax rate
- 23.0%
- Other income, % of PBT
- 39.8%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹5,286 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.4%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹820 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 89.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 76.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹358 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 397.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹65.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 18.8%
Solvency and efficiency
- Current ratio
- 3.85
- Debt / Equity
- 0.18
- Debt / Assets
- 0.12
- Debt / EBITDA
- 1.44
- Interest coverage
- 5.78
- Financial leverage
- 1.42
- CFO / Net profit
- 0.92
- Cash / Market cap
- 21.0%
- Cash per share
- ₹35.29
- Asset turnover
- 0.46
- Fixed asset turnover
- 1.68
- Capital intensity
- 0.59
- Debtor days
- 111 days
- Inventory turnover
- 1.82
- Cash conversion cycle
- 119 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹13 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹4,245 Cr |
| Sales | Operating profit | ₹1,041 Cr |
| Operating profit | Interest | ₹115 Cr |
| Operating profit | Depreciation | ₹222 Cr |
| Operating profit | Profit before tax | ₹704 Cr |
| Other income | Profit before tax | ₹207 Cr |
| Profit before tax | Tax and other | ₹220 Cr |
| Profit before tax | Net profit | ₹691 Cr |
Revenue and net profit
Revenue grew 20.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹2,939 Cr | ₹572 Cr |
| FY2022 | ₹3,340 Cr | ₹368 Cr |
| FY2023 | ₹3,443 Cr | ₹70 Cr |
| FY2024 | ₹4,390 Cr | ₹391 Cr |
| FY2025 | ₹5,286 Cr | ₹691 Cr |
Cash flows
FY2025: ₹549 Cr from operations, -₹3.00 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹35 Cr | -₹4,348 Cr |
| FY2022 | ₹249 Cr | -₹916 Cr |
| FY2023 | ₹72 Cr | -₹363 Cr |
| FY2024 | ₹358 Cr | -₹277 Cr |
| FY2025 | ₹549 Cr | -₹3 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹5,286 Cr+20.4%1Y
- Net profit
- ₹691 Cr+76.7%1Y
- Cash from operations
- ₹549 Cr
- Free cash flow
- -₹3 Cr
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹5,286 Cr | ₹1,041 Cr | — | ₹691 Cr | ₹549 Cr | -₹3 Cr | 9.3% | +20.4% | +76.7% |
Monthly returns
Month-by-month returns of PPLPHARMA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹10,392 Cr |
| Equity capital | ₹1,324 Cr |
| Reserves | ₹6,128 Cr |
| Borrowings | ₹1,243 Cr |
| Other liabilities | ₹1,696 Cr |
| Assets | ₹10,392 Cr |
| Fixed assets | ₹2,894 Cr |
| Capital work in progress | ₹327 Cr |
| Investments | ₹3,105 Cr |
| Other assets | ₹4,065 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
PPLPHARMA trades at 31.7x earnings against a peer median of 52.6x (a 40% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| PIRAMAL PHARMA LIMITEDPPLPHARMAthis companyP/E ↓ discount | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Dr. Lal Pathlabs LimitedLALPATHLAB | ₹23,777 Cr | 45.0x | 10.2x | 20.2% | 38.3x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Onesource Specialty Pharma LimitedONESOURCE | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Eris Lifesciences LimitedERIS | ₹20,131 Cr | 71.4x | 7.3x | 11.9% | 45.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
PPLPHARMA since 1 January, against earlier years.
Historical volatility
PPLPHARMA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 21.0% |
| FY2022 | 14.0% |
| FY2023 | 3.0% |
| FY2024 | 14.0% |
| FY2025 | 20.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹5,286 Cr |
| Costs | |
| Interest | ₹115 Cr |
| Expenses | ₹4,245 Cr |
| Operating profitOperating Profit | ₹1,041 Cr |
| Other income and charges | |
| Profit before tax | ₹911 Cr |
| Tax | |
| Net profitNet Profit | ₹691 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹10,392 Cr |
| Equity capitalEquity Capital | ₹1,324 Cr |
| Reserves | ₹6,128 Cr |
| Borrowings | ₹1,243 Cr |
| Other liabilitiesOther Liabilities | ₹1,696 Cr |
| AssetsTotal Assets | ₹10,392 Cr |
| Fixed assetsFixed Assets | ₹2,894 Cr |
| Capital work in progressCWIP | ₹327 Cr |
| Investments | ₹3,105 Cr |
| Other assetsOther Assets | ₹4,065 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹549 Cr |
| Investing cash flowCash from Investing Activity | -₹552 Cr |
| Financing cash flowCash from Financing Activity | -₹62 Cr |
| Change in cashNet Cash Flow | -₹65 Cr |
Learn while you research
Academy chapters picked for PIRAMAL PHARMA LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 31.7, learn when high multiples are justified.6 min read
- 04 Growth Investing20% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read